<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112877">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633788</url>
  </required_header>
  <id_info>
    <org_study_id>195263-006</org_study_id>
    <nct_id>NCT01633788</nct_id>
  </id_info>
  <brief_title>A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in
      patients with meibomian gland dysfunction (MGD) in the eyelids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Meibum Quality Score Assessed by the Investigator on a 4-Point Scale</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Overall Ocular Discomfort on a 5-Point Scale</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>AGN-195263 Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop of AGN-195263 Formulation A will be instilled in each eye twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-195263 Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop of AGN-195263 Formulation B will be instilled in each eye twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-195263 Formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop of AGN-195263 Formulation C will be instilled in each eye twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-195263 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-195263 Formulation A</intervention_name>
    <description>1 drop of AGN-195263 Formulation A will be instilled in each eye twice daily.</description>
    <arm_group_label>AGN-195263 Formulation A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-195263 Formulation B</intervention_name>
    <description>1 drop of AGN-195263 Formulation B will be instilled in each eye twice daily.</description>
    <arm_group_label>AGN-195263 Formulation B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-195263 Formulation C</intervention_name>
    <description>1 drop of AGN-195263 Formulation C will be instilled in each eye twice daily.</description>
    <arm_group_label>AGN-195263 Formulation C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-195263 Vehicle</intervention_name>
    <description>1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.</description>
    <arm_group_label>AGN-195263 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meibomian gland dysfunction in both eyes

          -  Best-corrected visual acuity of 20/40 or better in each eye

        Exclusion Criteria:

          -  Known or suspected prostate cancer

          -  History of breast cancer

          -  Using LATISSEÂ® or any other eye lash growth-stimulating product at least 30 days
             prior to the screening visit, or anticipated use during the study

          -  Contact lens wear in either eye during any portion of the study

          -  Unable to instill eye drops correctly

          -  History of corneal refractive surgery in either eye within 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 15, 2015</lastchanged_date>
  <firstreceived_date>July 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
